Kymera Investor Presentation Deck

● Partial Response and Stable Disease Observed Across Multiple Tumor Types During Dose Escalation of KT-333 ASH Poster Presentation (Data Cut-off of October 18, 2023) ● Overall Response in Evaluable Patients* Non-CTCL Lymphoma/ Hodgkin's (n=3) Partial Response Stable Disease Progression of Disease 1 0 CTCL (n=5) 2 1 Solid Tumor (n=12) 0 4 KYMERA ©2023 KYMERA THERAPEUTICS, INC. 2 2 8 * Two LGL-L patients at DL5 not included as they were not evaluable for response assessment at time of KT- 333 discontinuation Duration on Treatment for Patients with Response of SD or Better Hodgkin's CTCL CTCL CTCL HNC1 HNC2 Cholangiocarcinoma Renal ¥ Ongoing Disease Progression Partial Response Stable Disease C8 Summary: Disease control in 3 of 5 CTCL patients including 2 PR's and 1 PR in cHL demonstrate activity in liquid tumors supported by preclinical data DL2 DL3 DL4 C2 C3 C4 C5 C6 C7 * Received steroids during 1st week of C1 to treat symptoms arising from Szezary Syndrome ¥ Discontinued d/t AE (Gr. 2 squamous cell carcinoma of skin) HNC1 = Mucoepidermoid carcinoma of parotid gland Discontinued d/t Pl discretion (stable disease at discontinuation) HNC2 = Sinonasal adenocarcinoma Stable disease observed in 4 solid tumor patients to date with potential pattern of more prolonged SD in H&N tumors Enrollment moving forward to continue enriching for tumor types potentially responsive to monotherapy or anti-PD-1 combination PAGE 46

View entire presentation